# Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

> **NCT06617715** · PHASE3 · RECRUITING · sponsor: **Sinovac Life Sciences Co., Ltd.** · enrollment: 3080 (estimated)

## Conditions studied

- Pneumococcal Infectious Disease

## Interventions

- **BIOLOGICAL:** Sinovac PCV13
- **BIOLOGICAL:** Prevnar®

## Key facts

- **NCT ID:** NCT06617715
- **Lead sponsor:** Sinovac Life Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-23
- **Primary completion:** 2026-05-12
- **Final completion:** 2026-07-30
- **Target enrollment:** 3080 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06617715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06617715, "Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06617715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*